Use of the Hedgehog signaling pathway inhibitor in the treatment of recurrent locally advanced and metastatic basal cell skin cancer
Open Access
- 7 February 2020
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
Abstract
The study objective is to provide data on the use of the Hedgehog signaling pathway inhibitor (vismodegib) in the treatment of recurrent locally advanced and metastatic basal cell skin cancer at the N. N. Petrov National Medical Research Center of Oncology.Materials and methods. Clinical data of 10 patients who participated in a multicenter, non-randomized clinical trial of phase II ERIVANCE BBC (ClinicalTrials. gov NCT833417). Patients took the daily studied drug vismodegib orally at a dose of 150 mg daily until disease progression or intolerance due to side effects. Efficiency and safety assessment was carried out once every 4 weeks.Results. Complete regression was achieved in 7 patients, while the average duration of use of the drug was 240 ± 65 days. Stabilization was observed in 2 patients, the minimum duration of the drug was 336 days. One patient showed progression after 728 days of taking the drug. Side effects of the 1 grade according to CTCAE (Common Terminology Criteria for Adverse Events), v. 3.0 were observed in all patients, in 9 they were expressed in muscle cramps, alopecia and changes in taste sensitivity, and in 1 patient isolated in the form of muscle cramps.Conclusion. The results show a good safety profile of vismodegib, which allows it to be used in elderly patients with concomitant pathology. The frequency of response to treatment, including the achievement of complete regression in 70 % of patients, makes vismodegib an acceptable treatment option for metastatic form of basal cell skin cancer and relapse of locally advanced forms.Keywords
This publication has 11 references indexed in Scilit:
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialThe Lancet Oncology, 2015
- Basal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and MenAmerican Journal of Epidemiology, 2013
- Profile of vismodegib and its potential in the treatment of advanced basal cell carcinomaCancer Management and Research, 2013
- Advanced basal cell carcinoma of the skinCurrent Opinion in Oncology, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2012
- Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive DiseaseJournal of Skin Cancer, 2010
- Neglected Basal Cell Carcinomas in the 21st CenturyJournal of Skin Cancer, 2010
- Sonic hedgehog signaling in basal cell carcinomasCancer Letters, 2005
- Activating Smoothened mutations in sporadic basal-cell carcinomaNature, 1998
- Metastatic basal cell carcinoma: Report of twelve cases with a review of the literatureJournal of the American Academy of Dermatology, 1991